Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Kaplan-Meier Approach01:24

Kaplan-Meier Approach

The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
Reliability and Validity01:29

Reliability and Validity

Reliability and validity are two important considerations that must be made with any type of data collection. Reliability refers to the ability to consistently produce a given result. In the context of psychological research, this would mean that any instruments or tools used to collect data do so in consistent, reproducible ways.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predicting the Treatment Regimen Estimand in Phase 3 Studies from the Estimated Efficacy Estimand Based on Phase 2 Data.

Therapeutic innovation & regulatory science·2026
Same author

Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWIND.

Diabetes care·2026
Same author

Relationships Between Metabolic and Bariatric Surgery and Adverse Kidney Outcomes: An Analysis of a Retrospective Cohort.

Obesity science & practice·2025
Same author

Bayesian Integrated Learning of Longitudinal Dose-Response Relationships via Decentralized Clinical Trials.

Statistics in medicine·2025
Same author

Estimand Endpoints for Longitudinal Measures of Continuous Disease Progression with an Alzheimer's Disease Example.

Therapeutic innovation & regulatory science·2025
Same author

Estimating risk of consequences following hypoglycaemia exposure using the Hypo-RESOLVE cohort: a secondary analysis of pooled data from insulin clinical trials.

Diabetologia·2024

Related Experiment Video

Updated: May 17, 2026

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

Evaluation of a surrogate marker: validity and efficiency.

Yongming Qu1

  • 1Department of Global Statistical Science, Eli Lilly and Company, Indianapolis, IN 46285, USA. quyo@lilly.com

Statistics in Medicine
|November 8, 2012
PubMed
Summary

Evaluating surrogate endpoints and markers lacks consensus. This study clarifies definitions and proposes using "proportion of information gain" to assess surrogate marker validity, aiding statistical validation in clinical research.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

Multimodal Cross-Device and Marker-Free Co-Registration of Preclinical Imaging Modalities
07:13

Multimodal Cross-Device and Marker-Free Co-Registration of Preclinical Imaging Modalities

Published on: October 27, 2023

Related Experiment Videos

Last Updated: May 17, 2026

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

Multimodal Cross-Device and Marker-Free Co-Registration of Preclinical Imaging Modalities
07:13

Multimodal Cross-Device and Marker-Free Co-Registration of Preclinical Imaging Modalities

Published on: October 27, 2023

Area of Science:

  • Biostatistics
  • Clinical Trial Methodology
  • Pharmacometrics

Background:

  • Statistical validation of surrogate endpoints and markers is a long-standing challenge.
  • A lack of consensus exists regarding the evaluation methods for surrogate endpoints and markers.
  • Confusion persists about the appropriate statistical approaches for surrogate marker evaluation.

Purpose of the Study:

  • To clarify the statistical definitions of surrogate endpoints and surrogate markers.
  • To introduce the concepts of validity and efficiency for surrogate markers.
  • To propose a novel metric for evaluating surrogate marker validity.

Main Methods:

  • Review and clarification of existing statistical definitions.
  • Introduction of the concepts of validity and efficiency.
  • Proposal of the 'proportion of information gain' as an evaluation metric.

Main Results:

  • Clearer statistical definitions for surrogate endpoints and markers are provided.
  • The concepts of validity and efficiency are formally introduced.
  • The 'proportion of information gain' is suggested as a method to evaluate surrogate marker validity.

Conclusions:

  • The proposed 'proportion of information gain' offers a standardized approach to assessing surrogate marker validity.
  • This metric can help resolve the ongoing confusion in statistical validation methods.
  • Improved validation of surrogate markers can enhance clinical trial efficiency and drug development.